DB-1305/BNT325 was generally well tolerated and exhibited “very encouraging and durable antitumor activity in ovarian cancer patients,” said Maria Rubinstein, MD.

Researchers from Heidelberg Pharma AG have presented a new antibody-drug conjugate (ADC) that shows promise for treating pancreatic ductal adenocarcinoma (PDAC). The ADC, called hRS7 ATAC, targets ...

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...

Lotte Biologics Co., the biotech arm of Lotte Group, said Thursday it has signed a deal with an Asia-based biotech company ...

The startup, Veraxa, has $253 million in cash and is raising a crossover funding round to support a pipeline of T cell ...

Zymeworks presents six posters at AACR highlighting advancements in antibody-drug conjugates and T cell engagers, including ZW209's promise in lung cancer. Zymeworks Inc. announced the ...

LUND, SWEDEN / ACCESS Newswire / April 25, 2025 / Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today released a poster with new preclinical data that strengthens the rationale behind the ...

and TAIPEI, April 21, 2025 /PRNewswire/ -- Acepodia (6976: TT) today announced the presentation of new preclinical data highlighting its proprietary dual-payload antibody-drug conjugate (AD2C ...

Our team of proven drug developers is advancing an antibody-drug conjugate with our proprietary linker technology, a T-cell engager with wide therapeutic window, and a multi-functional checkpoint ...